Commercially Supported Symposia
HOPA invites its Industry and Medical Education Partners to submit proposals for commercially supported symposia (CSS) to take place during HOPA's Annual Conference, March 29 - April 1, 2023. HOPA welcomes applications for clinically relevant, scientifically sound, and unbiased programs that will provide oncology pharmacists with novel and innovative approaches to patient care.
All CSS applications will be reviewed by the HOPA Program Committee to ensure they meet educational standards, fulfill clear educational objectives, meet the educational needs and are free of commercial bias. Commercial supporters may not dictate the content of symposia or the selection of faculty. HOPA will not provide continuing education credit for CSS. Evaluation and CPE Certificates/Certificates of Attendance are the responsibility of the CPE CSS provider.
Please email info@hoparx.org, with any questions.
The call for proposals for commercially supported symposia is now open.
Exhibitor Prospectus (PDF)
Supporters can develop and provide a 1-2 hour promotional or educational program in accordance with their own guidelines at the Annual Conference or at the Practice Management Program. These activities do not compete with CE programs, affording you an opportunity to present your product as a workshop to present branded or non-branded information to attendees.
Corporate-sponsored symposia opportunities are currently sold out. Other sponsorship opportunities are still available. Please contact Laurie Rappa, lrappa@hoparx.org with questions.
The in-person annual Transplantation & Cellular Therapy Meetings of ASTCT™ (American Society for Transplantation and Cellular Therapy) and CIBMTR® (Center for International Blood and Marrow Transplant Research) took place from February 15-19, 2023 in Orla
The initiative will provide support and guidance to community hematologists/oncologists on the risk-stratification of MDS, selection of evidence-based and novel therapies for the management of anemia in patients with lower-risk MDS, and on best practices
